Functional interaction between NMDA and mGlu5 receptors: Effects on working memory, instrumental learning, motor behaviors, and dopamine release

Neuropsychopharmacology

Volumn 29, Issue 7, 2004, Pages 1259-1269

  Homayoun, Houman ^a   Stefani, Mark R ^a   Adams, Barbara W ^b   Tamagan, Gilles D ^b   Moghaddam, Bits ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Glutamate; Metabotropic glutamate receptors; Nucleus accumbens; Prefrontal cortex; Schizophrenia

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; DIZOCILPINE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CELL INTERACTION; COGNITION; CONTROLLED STUDY; DOPAMINE RELEASE; INSTRUMENTAL CONDITIONING; LEARNING; LOCOMOTION; MALE; MOLECULAR INTERACTION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; STEREOTYPY; WORKING MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; MICRODIALYSIS; MOTOR ACTIVITY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOTYPED BEHAVIOR;

EID: 2942650911     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300417     Document Type: Article

References (65)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
2. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 15: 750-757.
3. Alagille D, Baldwin RM, Tamagnan G (2003). Synthesis and SAR of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity. American Chemical Society meeting 226: 172.
4. Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF et al (2001). Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411: 962-965.
5. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994). Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116: 143-151.
6. Attucci S, Albani-Torregrossa S, Moroni F, Pellegrini-Giampietro DE (2001). Metabotropic glutamate receptors stimulate phospholipase D via different pathways in the adult and neonate rat hippocampus. Neurochem Res 26: 1151-1155.
7. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20: 7871-7879.
8. Baldwin AE, Holahan MR, Sadeghian K, Kelley AE (2000). N-methyl-D-aspartate receptor-dependent plasticity within a distributed corticostriatal network mediates appetitive instrumental learning. Behav Neurosci 114: 84-98.
9. Baldwin AE, Sadeghian K, Kelley AE (2002). Appetitive instrumental learning requires coincident activation of NMDA and dopamine D1 receptors within the medial prefrontal cortex. J Neurosci 22: 1063-1071.
10. Balschun D, Manahan-Vaughan D, Wagner T, Behnisch T, Reymann KG, Wetzel W (1999). A specific role for group I mGluRs in hippocampal LTP and hippocampus-dependent spatial learning. Learn Memory 6: 138-152.
11. Balschun D, Wetzel W (2002). Inhibition of mGluR5 blocks hippocampal LTP in vivo and spatial learning in rats. Pharmacol Biochem Behav 73: 375-380.
12. Benquet P, Gee C, Gerber U (2002). Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. J Neurosci 22: 9679-9686.
13. Bleakman D, Rusin KI, Chard PS, Glaum SR, Miller RJ (1992). Metabotropic glutamate receptors potentiate ionotropic glutamate responses in the rat dorsal horn. Mol Pharmacol 42: 192-196.
14. Bordi F, Ugolini A (1999). Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 59: 55-79.
15. Bruno V, Ksiazek I, Battaglia G, Lukic S, Leonhardt T, Sauer D et al (2000). Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39: 2223-2230.
16. Carlezon WA, Wise RA (1996). Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 16: 3112-3122.
17. Cartmell J, Schoepp DD (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907.
18. Chapman AG, Nanan K, Williams M, Meldrum BS (2000). Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styrylpyridine (SIB 1893). Neuropharmacology 39: 1567-1574.
19. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S et al (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4: 873-874.
20. Chojnacka-Wojcik E, Klodzinska A, Pilc A (2001). Glutamate receptor ligands as anxiolytics. Curr Opin Invest Drugs 2: 1112-1119.
21. Conn JP, Pin J-P (1997). Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 37: 205-237.
22. Coyle J (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3: 241-253.
23. Coyle JT, Tsai G, Goff DC (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets 1: 183-189.
24. Dember WN, Richman CL (1989). Spontaneous Alternation Behavior. Springer-Verlag: New York. 212pp.
25. Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE (1997). (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36: 265-267.
26. Geyer M, Moghaddam B (2002). Animal models relevant to schizophrenia disorder. In: Davis KL, Charney C, Coyle JT and Nemeroff C (eds). Psychopharmacology: The Fifth Generation of Progress. Lippincott, Williams and Wilkins: Philadelphia.
27. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
28. Harrison PJ, Owen MJ (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361: 417-419.
29. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002). The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43: 1199-1209.
30. Hoffman DC, Donovan H, Cassella JV (1993). The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berlin) 111: 339-344.
31. Hooper N, Fraser C, Stone TW (1996). Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology 123: 250-257.
32. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
33. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1236.
34. Kemp JA, McKernan RM (2002). NMDA receptor pathways as drug targets. Nat Neurosci 5: 1039-1042.
35. Kinney G, Burno M, Campbell U, Hernandez L, Rodriguez D, Bristow L et al (2003). Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Therap 306: 116-123.
36. Kinney G, Wittmann M, Bristow L, Campbell U, Conn P (2002). Behavioral consequences of mGluR5 and NMDA receptor antagonist interaction: implications for schizophrenia. Neuropharmacology 43: 292.
37. Kokkinidis L, Anisman H (1976). Interaction between cholinergic and catecholaminergic agents in a spontaneous alternation task. Psychopharmacology 48: 261-270.
38. Kozela E, Pilc A, Popik P (2003). Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165: 245-251.
39. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmaclogy 169: 215-233.
40. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
41. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
42. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM et al (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17: 5196-5205.
43. Luby E, Cohen B, Rosenbaum G, Gottlieb J, Kelley R (1959). Study of a new schizophrenomimetic drug-sernyl. Am Med Assoc Arch Neurol Psychiatry 81: 363-369.
44. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
45. Manahan-Vaughan D, Schuetz K (2002). Differential participation of metabotropic glutamate receptor mGlu1 and mGlu5 in spatial learning and hippocampal long-term potentiation in vivo. Neuropharmacology 43: 297.
46. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001). Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21: 5925-5934.
47. Moghaddam B (2003). Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881-884.
48. Morisset V, Nagy F (1996). Modulation of regenerative membrane properties by stimulation of metabotropic glutamate receptors in rat deep dorsal horn neurons. J Neurophysiol 76: 2794-2798.
49. Ogren SO, Goldstein M (1994). Phencyclidine and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11: 167-177.
50. Olney J, Farber N (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
51. Paterson NE, Semenova S, Gasparini F, Markou A (2003). The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167: 257-264.
52. Paxinos G, Watson C (1986). The Rat Brain in Stereotoxic Coordinates, 4th edn Academic Press: San Diego.
53. Pisani A, Calabresi P, Centonze D, Bernardi G (1997). Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Brit J Pharmacol 120: 1007-1014.
54. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D et al (2001). Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106: 579-587.
55. Ragozzino ME, Unick KE, Gold PE (1996). Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA 93: 4693-4698.
56. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355: 455-469.
57. Sawaguchi T, Goldman-Rakic P (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947-950.
58. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163: 53-57.
59. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Therap 295: 1267-1275.
60. Steinpreis RE, Sokolowski J, Papanikolaou A, Salamone JD (1994). The effects of haloperidol and clozapine on PCP and amphetamine induced suppression of social behavior. Pharmacol Biochem Behav 47: 579-585.
61. Tamminga CA (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21-36.
62. Thomas LS, Jane DE, Gasparini F, Croucher MJ (2001). Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 41: 523-527.
63. Ugolini A, Corsi M, Bordi F (1997). Potentiation of NMDA and AMPA responses by group I mGluR in spinal cord motor neurons. Neuropharmacology 36: 1047-1055.
64. Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379.
65. Wolf ME (1998). The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54: 679-720.